Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | -5.93% | 158.00 | 0.0% | $686.24m | |
| AMGN | Amgen, Inc. | -0.25% | 250.58 | 1.5% | $604.45m | |
| GILD | Gilead Sciences, Inc. | -0.47% | 66.02 | 1.0% | $437.82m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -1.24% | 299.23 | 1.9% | $414.73m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -1.91% | 636.34 | 2.6% | $364.61m | |
| ILMN | Illumina, Inc. | -3.10% | 213.02 | 3.3% | $317.77m | |
| SNSS | Sunesis Pharmaceuticals, Inc. | -0.98% | 4.06 | 0.7% | $283.81m | |
| NVAX | Novavax, Inc. | -8.19% | 39.37 | 75.7% | $258.88m | |
| BIIB | Biogen, Inc. | -0.94% | 217.58 | 1.8% | $192.12m | |
| BNTX | BioNTech SE | -5.19% | 152.04 | 0.0% | $149.19m | |
| GOVX | GeoVax Labs, Inc. | 0.44% | 2.26 | 0.0% | $119.92m | |
| BMRN | BioMarin Pharmaceutical, Inc. | -0.20% | 94.84 | 4.2% | $100.34m | |
| SAVA | Cassava Sciences, Inc. | 27.26% | 25.72 | 0.0% | $95.08m | |
| CRSP | CRISPR Therapeutics AG | -5.42% | 71.74 | 0.6% | $92.05m | |
| PACB | Pacific Biosciences of California, Inc. | -4.88% | 7.61 | 6.2% | $87.70m |
Company Profile
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics & Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics & Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded in 1976 and is headquartered in Minneapolis, MN.